← Back to headlines
Teva Pharmaceuticals Reports Strong Q1 Earnings, Plans Emalex Acquisition
Teva Pharmaceutical Industries announced its first-quarter earnings, showing a surge in AUSTEDO sales. The company also revealed plans for a $700 million buyout of Emalex.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
